Page last updated: 2024-10-31

neostigmine and Bronchial Spasm

neostigmine has been researched along with Bronchial Spasm in 7 studies

Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.

Bronchial Spasm: Spasmodic contraction of the smooth muscle of the bronchi.

Research Excerpts

ExcerptRelevanceReference
"Sugammadex and neostigmine given to reverse residual neuromuscular blockade can cause side effects including bradycardia, anaphylaxis, bronchospasm, and even cardiac arrest."4.12Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects. ( Chahar, P; Chhabada, S; Khanna, S; Li, K; Maheshwari, K; Ruetzler, K; Schmidt, MT; Sessler, DI; Turan, A; Yang, D, 2022)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19904 (57.14)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Ruetzler, K1
Li, K1
Chhabada, S1
Maheshwari, K1
Chahar, P1
Khanna, S1
Schmidt, MT1
Yang, D1
Turan, A1
Sessler, DI1
USPENSKAIA, EP2
Hazizaj, A1
Hatija, A1
Sun, KO1
Pratt, CI1
Droszcz, W1
Bogoslawski, RW1
Belik, IE1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery[NCT01748643]Phase 460 participants (Actual)Interventional2013-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Surgery

Measured from the time of first skin incision to completion of skin closure. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionminutes (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex61.3
Normal Neuromuscular Blockade, Reversal With Neostigmine70.6

Forced Expiratory Volume in 1 Second

Forced expiratory volume in 1 second is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex45.2
Normal Neuromuscular Blockade, Reversal With Neostigmine48.8

Forced Vital Capacity

Forced vital capacity is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex51.9
Normal Neuromuscular Blockade, Reversal With Neostigmine49.0

Number of Intra-abdominal Pressure Rises > 18cmH2O

The number of intra-abdominal pressure rises > 18cmH2O detected by the intra-abdominal CO2 insufflator. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionnumber of intra-abdominal pressure rises (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex0.2
Normal Neuromuscular Blockade, Reversal With Neostigmine0.3

Peak Expiratory Flow

Peak expiratory flow is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex51.3
Normal Neuromuscular Blockade, Reversal With Neostigmine51.5

Subjective Evaluation of the View on the Operating Field by the Surgeon

"At the end of surgery, the view on the operating field will be graded by the surgeon using a 5-point rating scale:~Extremely poor~Poor~Acceptable~Good~Optimal" (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex4.2
Normal Neuromuscular Blockade, Reversal With Neostigmine3.9

Other Studies

7 other studies available for neostigmine and Bronchial Spasm

ArticleYear
Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects.
    Anesthesia and analgesia, 2022, 05-01, Volume: 134, Issue:5

    Topics: Anaphylaxis; Bradycardia; Bronchial Spasm; Child; Cohort Studies; Delayed Emergence from Anesthesia;

2022
[Experimental therapy of proserine bronchospasm].
    Biulleten' eksperimental'noi biologii i meditsiny, 1956, Volume: 42, Issue:8

    Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies,

1956
[Experimental therapy of proserine bronchospasm].
    Biulleten' eksperimental'noi biologii i meditsiny, 1956, Volume: 42, Issue:8

    Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies,

1956
[Experimental therapy of proserine bronchospasm].
    Biulleten' eksperimental'noi biologii i meditsiny, 1956, Volume: 42, Issue:8

    Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies,

1956
[Experimental therapy of proserine bronchospasm].
    Biulleten' eksperimental'noi biologii i meditsiny, 1956, Volume: 42, Issue:8

    Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies,

1956
Bronchospasm caused by neostigmine.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:1

    Topics: Adult; Anesthesia, General; Asthma; Bronchial Spasm; Cholinesterase Inhibitors; Humans; Male; Nasal

2006
Bronchospasm after esmolol and neostigmine.
    Anaesthesia and intensive care, 1993, Volume: 21, Issue:4

    Topics: Adrenergic beta-Antagonists; Appendectomy; Bronchial Spasm; Humans; Intraoperative Complications; Ma

1993
Bronchospasm after neostigmine.
    Anaesthesia, 1988, Volume: 43, Issue:3

    Topics: Bronchial Spasm; Humans; Intraoperative Complications; Neostigmine

1988
Investigations on the role of acetylcholine esterase in hypersensitivity states. II. Prostigmine provocation test in patients with bronchial asthma.
    Acta medica Polona, 1974, Volume: 15, Issue:4

    Topics: Acetylcholinesterase; Adult; Asthma; Bronchial Spasm; Humans; Middle Aged; Neostigmine; Respiratory

1974
[Experimental basis of surgical intervention in patients with bronchial asthma].
    Zentralblatt fur Chirurgie, 1967, Volume: 92, Issue:26a Pt 2

    Topics: Adolescent; Adult; Aged; Animals; Asthma; Bronchial Spasm; Carotid Sinus; Child; Denervation; Dogs;

1967